Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment

Liu, Xuan; Zhou, Xueqing; Shang, Xuwei; Wang, Li; Li, Yang; Yuan, Hong; Hu, Fuqiang

doi:10.1631/jzus.b1900468

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of DOX and siRNA-RAC1 enhances the antitumor activity of DOX against breast cancer cells via inhibition of EMT. 132 The antitumor effect of DOX is augmented by elevating its accumulation in cancer cells by inhibition of P-gp activity via siRNA. 133 The use of siRNA enables negative targeting of oncogene factors, such as STAT3, β-catenin, and Notch-1, which increases the antitumor activity of DOX.…”

Section: ■ Introductionmentioning

confidence: 67%

“…Down-regulation of RAC1 suppresses metastasis of cancer cells via inhibition of EMT. The use of DOX and siRNA-RAC1 enhances the antitumor activity of DOX against breast cancer cells via inhibition of EMT . The antitumor effect of DOX is augmented by elevating its accumulation in cancer cells by inhibition of P-gp activity via siRNA .…”

Section: Natural Compounds–sirna Co-deliverymentioning

confidence: 99%

See 1 more Smart Citation

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, codelivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.

show abstract

Section: ■ Introductionmentioning

confidence: 67%

Section: Natural Compounds–sirna Co-deliverymentioning

confidence: 99%

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It has been reported that EMT is a complex network, which includes multiple signaling pathways such as TGF-β family, Wnt, Notch, EGF, HGF, FGF, ect [ 8 ]. Furthermore, microRNAs, ROS, NF-κB, MAPKs, PI3K/Akt signaling pathways are validated to participate in regulating TGF- β-induced EMT [ 9 – 12 ]. Cucurbitacin B(CuB) is a natural compound derived from the Chinese herb Cucurbitaceae plant.…”

Section: Introductionmentioning

confidence: 99%

Cucurbitacin B inhibits TGF-β1-induced epithelial–mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways

et al. 2022

View full text Add to dashboard Cite

Background Lung cancer is the leading cause of cancer mortality worldwide, and most of the patients after treatment with EGF-TKIs develop drug resistance, which is closely correlated with EMT. Cucurbitacin B (CuB) is a natural product of the Chinese herb Cucurbitaceae plant, which has a favorable role in anti-inflammation and anti-cancer activities. However, the effect of CuB on EMT is still far from fully explored. In this study, the inhibition effect of CuB on EMT was investigated. Methods In this study, TGF-β1 was used to induce EMT in A549 cells. MTS assay was used to detect the cell viability of CuB co-treated with TGF-β1. Wound healing assay and transwell assay were used to determine the migration and invasion capacity of cells. Flow cytometry and fluorescence microscope were used to detect the ROS level in cells. Western blotting assay and immunofluorescence assay were used to detect the proteins expression. Gefitinib was used to establish EGF-TKI resistant NSCLC cells. B16-F10 intravenous injection mice model was used to evaluate the effect of CuB on lung cancer metastasis in vivo. Caliper IVIS Lumina and HE staining were used to detect the lung cancer metastasis of mice. Results In this study, the results indicated that CuB inhibited TGF-β1-induced EMT in A549 cells through reversing the cell morphology changes of EMT, increasing the protein expression of E-cadherin, decreasing the proteins expression of N-cadherin and Vimentin, suppressing the migration and invasion ability. CuB also decreased the ROS production and p-PI3K, p-Akt and p-mTOR expression in TGF-β1-induced EMT in A549 cells. Furthermore, Gefitinib resistant A549 cells (A549-GR) were well established, which has the EMT characteristics, and CuB could inhibit the EMT in A549-GR cells through ROS and PI3K/Akt/mTOR pathways. In vivo study showed that CuB inhibited the lung cancer metastasis effectively through intratracheal administration. Conclusion CuB inhibits EMT in TGF-β1-induced A549 cells and Gefitinib resistant A549 cells through decreasing ROS production and PI3K/Akt/mTOR signaling pathway. In vivo study validated that CuB inhibits lung cancer metastasis in mice. The study may be supporting CuB as a promising therapeutic agent for NSCLC and Gefitinib resistant NSCLC.

show abstract

“…Doxorubicin (DOX) is one of the most commonly used chemotherapy drugs for patients of breast cancer. However, drug resistance to DOX, partly due to the occurrence of EMT, can lead to recurrence and metastasis of cancer (154). Jin et al reported that RES successfully alleviated cell invasion and increased synergistic sensitivity to DOX via inhibiting the EMT process and modulating the association between silent information regulator 1 (SIRT1) and b-catenin.…”

Section: Non-digestive Cancersmentioning

confidence: 99%

Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors

et al. 2021

View full text Add to dashboard Cite

Epithelial-to-mesenchymal transition (EMT), a complicated program through which polarized epithelial cells acquire motile mesothelial traits, is regulated by tumor microenvironment. EMT is involved in tumor progression, invasion and metastasis via reconstructing the cytoskeleton and degrading the tumor basement membrane. Accumulating evidence shows that resveratrol, as a non-flavonoid polyphenol, can reverse EMT and inhibit invasion and migration of human tumors via diverse mechanisms and signaling pathways. In the present review, we will summarize the detailed mechanisms and pathways by which resveratrol and its analogs (e.g. Triacetyl resveratrol, 3,5,4’-Trimethoxystilbene) might regulate the EMT process in cancer cells to better understand their potential as novel anti-tumor agents. Resveratrol can also reverse chemoresistance via EMT inhibition and improvement of the antiproliferative effects of conventional treatments. Therefore, resveratrol and its analogs have the potential to become novel adjunctive agents to inhibit cancer metastasis, which might be partly related to their blocking of the EMT process.

show abstract

Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment

Cited by 9 publications

References 30 publications

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

Cucurbitacin B inhibits TGF-β1-induced epithelial–mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways

Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors

Contact Info

Product

Resources

About